TearSolutions

TearSolutions, Inc. is a startup company. TearSolutions primarily targets "dry eye disease," the most common ocular condition. Its mission is to develop a novel alternative therapy for dry eye through Phase II human clinical trials. At the core of the platform technology are the compelling tear protein "lacritin" and the patented drug "Lacripep."